Estriol succinate - Synthetic Biologics

Drug Profile

Estriol succinate - Synthetic Biologics

Alternative Names: Estriol - Synthetic Biologics; Oestriol - Synthetic Biologics; Trimesta

Latest Information Update: 08 Feb 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Institutes of Health (USA); University of California at Los Angeles
  • Developer Synthetic Biologics
  • Class Estrenes; Hormonal replacements
  • Mechanism of Action Estrogen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Multiple sclerosis

Most Recent Events

  • 08 Feb 2016 Discontinued - Phase-II for Multiple sclerosis (Adjunctive treatment) in USA (PO)
  • 02 Feb 2016 Synthetic Biologics terminates its licence for estriol succinate worldwide
  • 02 Feb 2016 Final efficacy data from a phase II trial in Multiple sclerosis released by Synthetic Biologics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top